Medical Condition News

RSS

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Fish oil induces severe colitis and colon cancer in mice

Fish oil - long encouraged by doctors as a supplement to support heart and joint health, among other benefits - induced severe colitis and colon cancer in mice in research led by Michigan State University and published this month in the journal Cancer Research.

6 Oct 2010

Researchers find exposure to air pollution increases severity of asthma symptoms

Exposure to dirty air is linked to decreased function of a gene that appears to increase the severity of asthma in children, according to a joint study by researchers at Stanford University and the University of California, Berkeley.

6 Oct 2010

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Cancer research is facing a radical change of direction. Cancer cells do not obtain their energy from the breakdown of sugar to carbon dioxide and water, but from energy-rich intermediates of sugar metabolism instead.

6 Oct 2010

Novel invasive surgery for children with scoliosis may eliminate need for spinal fusion

A novel minimally invasive surgery for young children living with a difficult-to-treat progressive form of scoliosis, known as juvenile idiopathic scoliosis, may eliminate the need for spinal fusion later in adolescence, according to new research by surgeons from Children's Mercy Hospitals and Clinics in Kansas City, Mo. The study was presented at the American Academy of Pediatrics National Conference and Exhibition in San Francisco.

6 Oct 2010

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Lixte Biotechnology Holdings announced today that the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), signed a NExT Material Transfer Agreement formalizing a collaboration with Lixte Biotechnology Holdings, Inc. for clinical evaluation of LB-100, one of Lixte's lead anti-cancer compounds.

6 Oct 2010

Knome announces winners of KnomeDISCOVERY Awards

Knome, Inc. today announced the winners of its inaugural KnomeDISCOVERY Awards, a program designed to spur new genetic insights into health.

6 Oct 2010

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.

5 Oct 2010

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

MRI technique may help predict decline in individuals with mild cognitive impairment

Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.

5 Oct 2010

Archimedes publishes FPNS clinical study results in Pain journal

Archimedes Pharma US Inc. today announced publication of results from a pivotal clinical study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

5 Oct 2010

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

IRIDEX Corporation today announced approval and commercial availability in Japan for its extended family of EndoProbe laser delivery devices. The EndoProbe is an intraocular laser delivery device used during vitreoretinal surgery for the treatment of multiple disorders including: diabetic retinopathy, retinal detachments and vitreous hemorrhage. IRIDEX distributes products in Japan through their partner, TOMEY Corporation.

5 Oct 2010

Caring.com introduces interactive Alzheimer’s resource for caregivers

Caring.com today launched Steps & Stages, the first-ever interactive guide, support system, and customized e-mail newsletter that delivers specific, stage-appropriate advice for those providing care for a loved one with Alzheimer's or another form of dementia.

5 Oct 2010

Majority of Canadians with asthma consider their disease 'well controlled'

A new survey, Asthma Insight and Management in Europe and Canada (EUCAN AIM), reveals that a majority of Canadians with asthma considered their disease "well controlled" at the time of the survey. However, in the year prior to the survey, more than half (52 per cent) required acute treatment for asthma, including seeing a doctor for worsening symptoms (45 per cent), unscheduled emergency room visits (28 per cent), and being hospitalized overnight (five per cent).

5 Oct 2010

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone for the treatment of growth hormone deficiency.

5 Oct 2010

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.

5 Oct 2010

ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company's clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI.

5 Oct 2010

Dr. Bessler joins Children's Hospital of Philadelphia

One of the world's leading experts in bone marrow failure and related blood disorders recently joined The Children's Hospital of Philadelphia. Hematology researcher Monica Bessler, M.D., Ph.D., arrived at the hospital this summer to establish a new program, the Pediatric and Adult Comprehensive Bone Marrow Failure Center.

5 Oct 2010

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

This study demonstrates that supplemental brief dynamic therapy in the treatment of patients with obsessive compulsive-disorder with concurrent major depressive disorder (who are receiving effective medication) has no significant clinical effect on both obsessive and depressive symptoms.

5 Oct 2010

AACR to host special conference on colorectal cancer

This October, the American Association for Cancer Research will host the special conference Colorectal Cancer: Biology to Therapy at the Loews Philadelphia Hotel. Hundreds of scientists, physicians and allied health professionals will gather and discuss new data on new screening methods and emerging therapies.

5 Oct 2010

Medical Condition News

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Fish oil induces severe colitis and colon cancer in mice

Researchers find exposure to air pollution increases severity of asthma symptoms

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Novel invasive surgery for children with scoliosis may eliminate need for spinal fusion

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Knome announces winners of KnomeDISCOVERY Awards

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

MRI technique may help predict decline in individuals with mild cognitive impairment

Archimedes publishes FPNS clinical study results in Pain journal

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

Caring.com introduces interactive Alzheimer’s resource for caregivers

Majority of Canadians with asthma consider their disease 'well controlled'

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

Dr. Bessler joins Children's Hospital of Philadelphia

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

AACR to host special conference on colorectal cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News